𝔖 Bobbio Scriptorium
✦   LIBER   ✦

2.217 PHARMACOKINETIC PROFILE OF THE SELECTIVE DOPAMINE D4 RECEPTOR ANTAGONIST L-745,870 IN THE MPTP-LESIONED NON-HUMAN PRIMATE MODEL OF PARKINSON'S DISEASE

✍ Scribed by P. Huot; J.B. Koprich; T.H. Johnston; S.H. Fox; J.M. Brotchie

Book ID
117754911
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
54 KB
Volume
18
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The nociceptin/orphanin FQ (NOP) recepto
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Naomi P. Visanji; Rob M.A. de Bie; Tom H. Johnston; Andrew C. McCreary; Jonathan 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

## Abstract The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration

Fipamezole (JP-1730) is a potent α2 adre
Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
✍ Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurs 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti

The selective mu-opioid receptor antagon
The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease
✍ James B. Koprich; Susan H. Fox; Tom H. Johnston; Allan Goodman; Bertrand Le Bour 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

## Abstract In Parkinson's disease (PD), dyskinesia develops following long‐term treatment with 3,4‐dihydroxyphenylalanine (L‐dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the

Histamine H3 receptor agonists reduce L-
Histamine H3 receptor agonists reduce L-dopa–induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Jordi Gomez-Ramirez; Tom H. Johnston; Naomi P. Visanji; Susan H. Fox; Jonathan M 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract L‐dopa–induced dyskinesia (LID) remains a major complication of the treatment of Parkinson's disease. The neural mechanisms underlying LID are thought to involve overactivity of striatal glutamatergic neurotransmission, with resultant underactivation of the output regions of the basal g